PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT01005576: Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia
Official title: A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial)
Conditions: Severe Thalassemia
Summary: This study is being done to determine if blood cell transplants, with either bone marrow or cord blood from unrelated donors, are effective in children with severe thalassemia and if this treatment approach has acceptable risks and side effects.
This study includes a preparative regimen with Hydroxyurea, Alemtuzumab, Fludarabine, Thiotepa and Melphalan that provides intense host immunosuppression without myeloablation. The primary hypothesis is that this regimen will promote stable engraftment of unrelated donor hematopoietic cells, support normal erythropoiesis, and result in an event free survival of > 75% of children with thalassemia major.
Interventions:
description: Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
name: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan
type: Drug
Study arms:
design_group_description: Hydroxyurea days -50 to -21 Alemtuzumab days -21 to -19 Fludarabine days -8 to -4 Thiotepa day -4 Melphalan day -3 Stem cell infusion day 0
design_group_title: Conditioning regimen
design_group_type: Experimental
Sponsor: Washington University School of Medicine
Collaborators: Pediatric Blood & Marrow Transplant Co.
Carelon Research, Inc.
Drug name mappings:
name: 磷酸氟达拉滨
lang: CN
name: Fludarabine Phosphate
lang: EN
name: フルダラビンリン酸エステル
lang: JP
name: 美法仑
lang: CN
name: Melphalan
lang: EN
name: メルファラン
lang: JP
name: 阿仑单抗
lang: CN
name: Alemtuzumab
lang: EN
name: アレムツズマブ（遺伝子組換え）
lang: JP
Clinical trial NCT00006105: Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer
Official title: Phase II Trial of Adjuvant Gemcitabine Plus Cisplatin With Amifostine Cytoprotection in Patients With Locally Advanced Bladder Cancer
Conditions: Bladder Cancer
Drug/Agent Toxicity by Tissue/Organ
Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as amifostine, may protect normal cells from the side effects of chemotherapy.
PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine, cisplatin, and amifostine following surgery in treating patients who have locally advanced bladder cancer.
Interventions:
name: amifostine trihydrate
type: Drug
name: cisplatin
type: Drug
name: gemcitabine hydrochloride
type: Drug
name: adjuvant therapy
type: Procedure
Study arms:
design_group_description: Subjects receive the study drug combination in 29-day cycles. Gemcitabine (1000 mg/m2) is given by IV infusion on Days 1, 8, and 15 of each cycle. Cisplatin (70 mg/m2) is given by IV infusion on Day 1 of each cycle. Immediately prior to each cisplatin infusion amifostine (910 mg/m2) will be given by IV infusion.
design_group_title: Administration of Cisplatin, Gemcitabine, and Amifostine
design_group_type: Experimental
Sponsor: The University of Chicago
Collaborators: National Cancer Institute
Drug name mappings:
name: 盐酸吉西他滨
lang: CN
name: Gemcitabine Hydrochloride
lang: EN
name: ゲムシタビン塩酸塩
lang: JP
name: 顺铂
lang: CN
name: Cisplatin
lang: EN
name: シスプラチン
lang: JP
Clinical trial NCT01991028: A Study to Investigate Lung Deposition of Radiolabelled OligoG
Official title: An Open Label, Randomised, Two-way Crossover Scintigraphic Study to Investigate Lung Deposition of Radiolabelled OligoG Delivered as a Dry Powder and as a Nebulised Solution in Cystic Fibrosis Patients
Conditions: Cystic Fibrosis
Summary: OligoG is a new potential treatment which is being developed by AlgiPharma AS (a Norwegian-based company) with an aim to help people with cystic fibrosis in the future.
OligoG, derived from marine algae, is expected to act locally in the lungs once inhaled to reduce mucus thickness and improve mucus clearance. It could also have the benefit of reducing the incidence of infections.
Nebulised doses of up to 540 mg/day have been administered to healthy volunteers for three consecutive days and to cystic fibrosis patients for 28 consecutive days. Both groups tolerated the medication well, with no treatment related issues reported. The dose administered in this study is lower; patients who complete the study will receive, in total, 186 mg of OligoG in two divided doses.
A new dry powder formulation of OligoG has been developed so that patients can use an inhaler, rather than a nebuliser. Administration from an inhaler compared to a nebuliser is much quicker and more practical for the patient.
In this study, we will use gamma scintigraphy to see where in the lungs the dry powder and nebulised solution go after being inhaled by cystic fibrosis patients. Gamma scintigraphy is a well-established medical imaging technique. A small amount of radioactive material will be added to both the dry powder and nebulised solution. The radiation emitted will then be detected by taking images using a device known as a gamma camera. The procedure is relatively easy and non-invasive.
The purpose of this study is to help answer the following research questions:
* How do the OligoG dry powder and nebulised solution distribute in the lungs of patients with cystic fibrosis?
* How much of the formulation gets to the deep lung?
* How much of the formulation remains in the devices used for administration?
Interventions:
description: Inhalation with dry powder by Mia Monodose Inhaler
name: Radiolabelled OligoG CF-5/20 DPI
other_name: Radiolabelled OligoG CF-5/20 Dry Powder for Inhalation
type: Drug
description: Inhalation with aerosolised solution by nebuliser
name: Radiolabelled OligoG CF-5/20 6% Solution
other_name: Radiolabelled OligoG CF-5/20 Solution
type: Drug
Study arms:
design_group_description: Single dose OligoG CF-5/20 Dry Powder for Inhalation by 3 capsules of 32mg OligoG via Miat Monodose Inhaler, radiolabelled ca10MBq 99mTc.
design_group_title: Radiolabelled OligoG CF-5/20 DPI
design_group_type: Experimental
design_group_description: Single dose of 1.5mL (90mg) aerosolised OligoG CF-5/20 6% solution via Sidestream Plus nebuliser, radiolabelled ca10MBq 99mTc.
design_group_title: Radiolabelled OligoG CF-5/20 6% Solution
design_group_type: Active Comparator
Sponsor: Bdd Pharma Ltd
Collaborators: AlgiPharma AS
Drug name mappings:
name: Oligo-G
lang: EN
Clinical trial NCT00063401: Phase II Study in Patients With Epidermal Growth Factor Receptor (EGFR) + Advanced Stage Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Official title: A Phase II Study of Cetuximab (C225)/Paclitaxel/Carboplatin for the Initial Treatment of Advanced Stage Ovarian, Primary Peritoneal, and Fallopian Tube Cancer
Conditions: Ovarian Cancer
Peritoneal Neoplasms
Fallopian Tube Neoplasms
Summary: The purpose of this study is to determine the progression-free survival obtained with cetuximab (C225)/paclitaxel/carboplatin in subjects with newly diagnosed advanced stage ovarian, primary peritoneal, or fallopian tube cancer.
Interventions:
description: 400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
name: Cetuximab:
other_name: Erbitux
type: Biological
description: 175 mg/m2 Day 1, six 21-day cycles
name: Paclitaxel
type: Drug
description: AUC = 6 Day1, six 21-day cycles
name: Carboplatin
type: Drug
Study arms:
design_group_description: Cetuximab 400 mg/m2 IV (over 120 minutes) on Day 1 of Cycle 1, followed by weekly maintenance doses of 250 mg/m2 IV (over 60 minutes). Paclitaxel 175 mg/m2 IC (over 3 hours) and carboplatin AUC of 6 IV (over 30 minutes) on Day 1 of each cycle. For eligible subjects, maintenance therapy will consist of cetuximab 250 mg/m2/week for up to 6 months.
design_group_title: 1
design_group_type: Experimental
Sponsor: Eli Lilly & Co.
Collaborators: Bristol Myers Squibb Co.
Drug name mappings:
name: 西妥昔单抗
lang: CN
name: Cetuximab
lang: EN
name: セツキシマブ（遺伝子組換え）
lang: JP
name: 白蛋白结合型紫杉醇
lang: CN
name: Albumin-Bound Paclitaxel
lang: EN
name: パクリタキセル(JAN)
lang: JP
name: 卡铂
lang: CN
name: Carboplatin
lang: EN
name: カルボプラチン
lang: JP
Clinical trial NCT01302483: Safety and Effectiveness of Kovacaine Nasal Spray for Dental Anesthesia
Official title: A Phase II, Single-Center, Randomized, Double-Blind, Active-Treatment-Controlled, Parallel-Group Study of the Efficacy of Kovacaine Nasal Spray for Anesthetizing Maxillary Teeth in Healthy Dental Patients
Conditions: Dental Anesthesia Efficacy
Summary: The purpose of this study was to determine the safety and efficacy of Kovacaine Mist (3% tetracaine HCl with 0.05% oxymetazoline HCl) for anesthesia of the maxillary teeth for dental procedures.
Interventions:
description: 1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
name: 3% tetracaine HCL with 0.05% oxymetazoline HCL
type: Drug
description: Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
name: Lidocaine Injection
type: Drug
Study arms:
design_group_description: 3% tetracaine HCL with 0.05% oxymetazoline HCL - Delivered via 3 sprays (100 uL) in each nostril
design_group_title: Kovacaine Nasal Spray
design_group_type: Experimental
design_group_description: .5 to 1 catridge of 2% lidocaine HCL with 1:100,000 epinephrine
design_group_title: Lidocaine Injection
design_group_type: Active Comparator
Sponsor: St. Renatus LLC
Collaborators: Ground Zero Pharmaceuticals
Rho, Inc.
Drug name mappings:
name: 盐酸羟甲唑啉
lang: CN
name: Oxymetazoline Hydrochloride
lang: EN
name: オキシメタゾリン塩酸塩
lang: JP
name: 盐酸丁卡因
lang: CN
name: Tetracaine Hydrochloride
lang: EN
Clinical trial NCT05824728: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Official title: Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis
Conditions: Parkinson Disease Psychosis
Summary: This clinical trial will test whether AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) can improve symptoms of psychosis in Parkinson's disease. Participants will be asked to complete up to 5 in-person study visits over approximately 20 weeks. Participants will receive both AGB101 and a placebo to take once a day for 6 weeks, with a 4-week washout in between. Participation will also involve physical/neurological exams, questionnaires, paper and pencil tests, providing blood and urine samples, and completing two MRI exams.
Interventions:
description: low-dose levetiracetam, 220 mg, extended release tablet
name: AGB101
other_name: levetiracetam
type: Drug
Study arms:
design_group_description: AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) once daily for 6 weeks, washout (4 weeks), then placebo capsule once daily for 6 weeks.
design_group_title: AGB101 first, then placebo
design_group_type: Experimental
design_group_description: Placebo capsule once daily for 6 weeks, washout (4 weeks), then AGB101 (low-dose levetiracetam, 220 mg, extended release tablet) once daily for 6 weeks.
design_group_title: placebo first, then AGB101
design_group_type: Experimental
Sponsor: The Johns Hopkins University
Collaborators: AgeneBio, Inc.
Drug name mappings:
name: 左乙拉西坦
lang: CN
name: Levetiracetam
lang: EN
name: レベチラセタム
lang: JP
Clinical trial NCT04484935: Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children
Official title: A Phase 2, Open-label, Uncontrolled, Single-dose Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Occurrence of Antidrug Antibody for Nirsevimab in Immunocompromised Children ≤ 24 Months of Age
Conditions: RSV Infection
Summary: Study D5290C00008 is a Phase 2, open-label, uncontrolled, single-dose study to evaluate the safety and tolerability, pharmacokinetic(s) (PK), occurrence of antidrug antibody (ADA), and efficacy of nirsevimab in immunocompromised children who are ≤ 24 months of age at the time of dose administration. Approximately 100 subjects will be enrolled. Subjects will be followed for approximately 1 year after dose administration.
Interventions:
description: Single fixed IM dose of nirsevimab 50 mg if body weight < 5 kg or 100 mg if body weight ≥ 5 kg, and subjects entering their second RSV season will receive a single fixed IM dose of nirsevimab 200 mg
name: Nirsevimab
other_name: Nirsevimab (MEDI8897)
type: Drug
Study arms:
design_group_description: 1st RSV season: 50mg nirsevimab<br/>1. st RSV season: 100mg nirsevimab<br/>2. nd RSV season: 200mg nirsevimab
design_group_title: Nirsevimab
design_group_type: Experimental
Sponsor: AstraZeneca PLC
Collaborators: IQVIA Holdings, Inc.
Drug name mappings:
name: 尼塞韦单抗
lang: CN
name: Nirsevimab
lang: EN
name: ニルセビマブ（遺伝子組換え） （JAN）
lang: JP
Clinical trial NCT00294931: Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Official title: A Phase II Trial of Irinotecan, Carboplatin, Bevacizumab in the Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Conditions: Carcinoma, Small Cell Lung
Summary: This multicenter phase II trial is designed to study the unique combination of chemotherapy (irinotecan./carboplatin) and bevacizumab in the extensive-stage setting. This clinical setting seems ideal for evaluation of the role of bevacizumab in delaying progression and prolonging survival.
Interventions:
name: irinotecan
type: Drug
name: carboplatin
type: Drug
name: bevacizumab
type: Drug
Study arms:
Sponsor: Scri Development Innovations LLC
Collaborators: Genentech, Inc.
Drug name mappings:
name: 卡铂
lang: CN
name: Carboplatin
lang: EN
name: カルボプラチン
lang: JP
name: 贝伐珠单抗
lang: CN
name: Bevacizumab
lang: EN
name: ベバシズマブ（遺伝子組換え）
lang: JP
name: 盐酸伊立替康
lang: CN
name: Irinotecan Hydrochloride
lang: EN
name: イリノテカン塩酸塩水和物
lang: JP
Clinical trial NCT03087071: Panitumumab With or Without Trametinib in Treating Patients With Stage IV Colorectal Cancer
Official title: A Phase II Enrichment Study of Panitumumab as a Single Agent or in Combination With Trametinib in Anti-EGFR-Refractory Stage IV Colorectal Cancer Patients
Conditions: EGFR NP_005219.2:p.S492R
KRAS Gene Mutation
MAP2K1 Gene Mutation
Metastatic Colorectal Adenocarcinoma
Refractory Colorectal Adenocarcinoma
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7
Summary: This phase II clinical trial studies how well panitumumab with or without trametinib works in treating patients with stage IV colorectal cancer. Immunotherapy with monoclonal antibodies, such as panitumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving panitumumab with or without trametinib may work better in treating patients with stage IV colorectal cancer.
Interventions:
description: Correlative studies
name: Laboratory Biomarker Analysis
type: Other
description: Given IV
name: Panitumumab
other_name: ABX-EGF
ABX-EGF Monoclonal Antibody
ABX-EGF, Clone E7.6.3
MoAb ABX-EGF
Monoclonal Antibody ABX-EGF
Vectibix
type: Biological
description: Given PO
name: Trametinib
other_name: GSK1120212
JTP-74057
MEK Inhibitor GSK1120212
Mekinist
type: Drug
Study arms:
design_group_description: Patients with EGFR ectodomain mutation receive panitumumab IV over 30-90 minutes on day 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
design_group_title: Cohort 1 (panitumumab)
design_group_type: Experimental
design_group_description: Patients with KRAS, NRAS, or BRAF mutation receive trametinib PO QD on days 1-14 and panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity.
design_group_title: Cohort 2 (panitumumab, trametinib)
design_group_type: Experimental
design_group_description: Patients without EGFR ectodomain, KRAS, NRAS, or BRAF mutation receive panitumumab as in Cohort 1. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Cohort 2.
design_group_title: Cohort 3 (panitumumab)
design_group_type: Experimental
Sponsor: The University of Texas MD Anderson Cancer Center
Collaborators: National Cancer Institute
Drug name mappings:
name: 二甲基亚砜曲美替尼
lang: CN
name: Trametinib dimethyl sulfoxide
lang: EN
name: トラメチニブ ジメチルスルホキシド付加物
lang: JP
name: 帕尼单抗
lang: CN
name: Panitumumab
lang: EN
name: パニツムマブ（遺伝子組換え）
lang: JP
Clinical trial NCT00130689: Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer
Official title: A Phase II Trial of Cetuximab in Unresectable or Metastatic Esophageal and Gastric Carcinoma
Conditions: Esophageal Cancer
Gastric Cancer
Neoplasm Metastasis
Summary: Purpose: There remains a great need for novel therapeutic agents and treatment strategies for advanced esophagogastric cancer. Preclinical and clinical studies have demonstrated increased EGFR expression in a significant proportion of both esophageal and gastric carcinomas. Inactivation of EGFR through use of a monoclonal antibody in preclinical models has resulted in inhibition of tumor growth. Agents designed to block the EGFR pathway have demonstrated disease control among previously treated patients with metastatic esophageal and gastric cancer. The proposed mechanism of action for cetuximab is its ability to effectively disrupt EGFR-mediated signal transduction pathways that ultimately leads to halting cell cycle progression, induces apoptosis, and also inhibits processes important for tumor growth, such as cell invasion and angiogenesis.
Interventions:
name: Cetuximab
other_name: erbitux
type: Drug
Study arms:
design_group_description: Patients received cetuximab at an initial dose of 400 mg/m2 administered IV over 120 min, followed by weekly infusions at 250 mg/m2 administered IV over 60 min. Once cycle was 4 weeks of therapy. Patients received treatment until disease progression or unacceptable toxicity.
design_group_title: Cetuximab
design_group_type: Other
Sponsor: Dana-Farber Cancer Institute, Inc.
Collaborators: The General Hospital Corp.
Bristol Myers Squibb Co.
Beth Israel Deaconess Medical Center, Inc.
Drug name mappings:
name: 西妥昔单抗
lang: CN
name: Cetuximab
lang: EN
name: セツキシマブ（遺伝子組換え）
lang: JP
Clinical trial NCT04523922: Oxytocin to Enhance Integrated Treatment for AUD and PTSD
Official title: Oxytocin to Enhance Integrated Exposure-Based Treatment of Co-occurring Alcohol Use Disorder and PTSD
Conditions: PTSD
Alcohol Use Disorder
Summary: The primary objective of the proposed Stage II study is to examine the efficacy of oxytocin (OT) as compared to placebo in reducing (1) alcohol use disorder (AUD) symptoms, and (2) post-traumatic stress disorder (PTSD) symptoms among Veterans receiving COPE therapy (Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure). To evaluate purported neurobiological mechanisms of change, we will employ functional magnetic resonance imaging (fMRI) at pre- and post-treatment.
Interventions:
description: 40 IU Intranasal Oxytocin self administered 30 minutes prior to each COPE session.
name: 40 IU Intranasal Oxytocin
other_name: oxytocin
type: Drug
description: Placebo (intranasal saline spray) self administered 30 minutes prior to each COPE session.
name: Placebo
other_name: saline
type: Drug
description: 12 weekly sessions of COPE therapy for PTSD and AUD.
name: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure
other_name: COPE
type: Behavioral
Study arms:
design_group_description: Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus intranasal Oxytocin.<br/>40-IU dose of Oxytocin self-administered 30 minutes prior to the start of each weekly COPE session.
design_group_title: Oxytocin Treatment Group
design_group_type: Experimental
design_group_description: Participants will receive 12 weekly sessions of Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE Therapy), plus placebo (intranasal saline spray).<br/>Intranasal dose of saline spray self-administered 30 minutes prior to the start of each weekly COPE session.
design_group_title: Placebo Group
design_group_type: Active Comparator
Sponsor: The Medical University of South Carolina
Collaborators: National Institute on Alcohol Abuse & Alcoholism
Drug name mappings:
name: 缩宫素
lang: CN
name: Oxytocin
lang: EN
name: オキシトシン
lang: JP
Clinical trial NCT04999137: Evaluation of Safety and Dosing of a Vitamin C Bundle for Sepsis Treatment in Africa
Official title: Evaluation of Pharmacokinetics, Safety and Feasibility for Administration of Two Doses of Intravenous Vitamin C Combined With Vitamin B1 for the Management of Adult Patients Admitted With Sepsis to Kiruddu National Referral Hospital
Conditions: Sepsis
Septic Shock
HIV
Summary: Open-label phase 2a Randomized Controlled Trial (RCT) assessing the pharmacokinetics of two different doses of intravenous vitamin C given alongside vitamin B1 in adult medical patients with sepsis and hypotension.
Interventions:
description: Vitamin C (ascor), infused intravenously in 50 mls sodium chloride (NaCl) over 30 minutes every 6 hours for 16 doses
name: Vitamin C
other_name: Ascor
Ascorbate
type: Drug
description: Vitamin B1 (200 mg) administered intravenously every 12 hours for 8 doses
name: Vitamin B1
other_name: Thiamin
Thiamine
type: Drug
Study arms:
design_group_description: intravenous vitamin C (1.5 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
design_group_title: Intravenous vitamin C 1.5g + intravenous vitamin B1
design_group_type: Experimental
design_group_description: Intravenous vitamin C (3 grams) every 6 hours for 16 doses in combination with intravenous vitamin B1 (200 mg) every 12 hours
design_group_title: Intravenous Vitamin C 3g + intravenous vitamin B1
design_group_type: Experimental
design_group_description: Usual care
design_group_title: Usual Care
design_group_type: No Intervention
Sponsor: Liverpool School of Tropical Medicine
Collaborators: University of Copenhagen
The University of Liverpool
Drug name mappings:
name: 盐酸硫胺素
lang: CN
name: Thiamine Hydrochloride
lang: EN
name: チアミン塩化物塩酸塩
lang: JP
name: 维生素C
lang: CN
name: Ascorbic Acid
lang: EN
name: アスコルビン酸
lang: JP
Clinical trial NCT00166543: Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
Official title: A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy
Conditions: Breast Cancer
Summary: This study is being done to find out how safe TAS-108 is and how well TAS-108 works on recurrent or recurrent inoperable breast cancer.
Interventions:
name: TAS-108
type: Drug
Study arms:
design_group_title: TAS-108 40 mg
design_group_type: Experimental
design_group_title: TAS-108 80 mg
design_group_type: Experimental
design_group_title: TAS-108 120 mg
design_group_type: Experimental
Sponsor: SRI International
Collaborators: Taiho Pharmaceutical Co., Ltd.
Drug name mappings:
name: SR-16234
lang: EN